Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
© Carey et al; licensee BioMed Central Ltd. 2005
Received: 25 November 2005
Accepted: 30 November 2005
Published: 30 November 2005
The original article was published in BMC Psychiatry 2005 5:5
The comment in the introduction of our article  suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics .
- Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005, 5: 5-10.1186/1471-244X-5-5.View ArticlePubMedPubMed CentralGoogle Scholar
- Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68: 29-39. 10.1016/S0024-3205(00)00911-5.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/5/44/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.